<DOC>
	<DOCNO>NCT02254304</DOCNO>
	<brief_summary>This Phase 4 , interventional , multicenter study subcutaneous Rebif® ( interferon beta-1a ) use RebiSmart™ device ass effectiveness adherence treatment subject clinically isolated syndrome ( CIS ) relapse multiple sclerosis ( RMS ) .</brief_summary>
	<brief_title>Effectiveness Rebif® Clinically Isolated Syndrome Relapsing Multiple Sclerosis Using RebiSmart™ ( PROCEED )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Male female subject 18 65 year age Female subject must neither pregnant breastfeeding must lack childbearing potential define protocol Subjects diagnose CIS RMS accord revise McDonald criterion ( 2010 ) Treatmentnaive subject subject treated Rebif® multidose inject RebiSmart™ longer 6 week prior Baseline visit Subjects able selfinject RebiSmart™ ( opinion physician ) Subjects Expanded Disability Status Scale ( EDSS ) score le ( &lt; ) 6 ( inclusive ) Baseline Signed inform consent subject data collection form Subjects experience relapse within 30 day Baseline Participation study within 30 day Baseline Received MS therapy within 6 month prior study enrolment ( example , diseasemodifying drug : immunomodulatory , immunosuppressive agent combination therapy ) exception Rebif® multidose inject RebiSmart™ Any visual physical impairment precludes subject selfinjecting treatment use RebiSmart™ Pregnancy breastfeed Serious acute heart disease uncontrolled cardiac dysrhythmias , uncontrolled angina pectoris , cardiomyopathy , uncontrolled congestive heart failure , per investigator opinion Current past ( within last 2 year ) history alcohol drug abuse Have contraindication treatment interferon beta1a accord Summary Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Relapsing multiple sclerosis</keyword>
	<keyword>Clinically isolated syndrome</keyword>
	<keyword>RMS</keyword>
	<keyword>CIS</keyword>
	<keyword>RebiSmart™</keyword>
	<keyword>Rebif®</keyword>
	<keyword>Interferon beta-1a</keyword>
</DOC>